Skip to main content
Fig. 3 | Cell Communication and Signaling

Fig. 3

From: TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer

Fig. 3

TMEM160 competitively binds to PD-L1 with SPOP, inhibiting its ubiquitination degradation. A The BioGRID database was used to search for the interacting proteins of TMEM160. B, C Endogenous Co-IP assays were performed in DLD1 and HCT116 cells to assess the interaction of TMEM160 with SPOP. D, E DLD1 and RKO cells were collected for western blotting analysis to investigate the effects of SPOP and TMEM160 overexpression on the expression PD-L1 in these cells. The whole-cell lysates were collected 48 h after transfection. F, G The Co-IP assay demonstrated that TMEM160 competes with SPOP for binding to PD-L1 in DLD1 and SW480 cells. H The results of the ubiquitination assay showed that competitive binding of TMEM160 to PD-L1 with SPOP reduces the ubiquitination degradation of PD-L1

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X